Advances in the treatment of diabetic retinopathy

Saudi Journal of Ophthalmology

Volumn 25, Issue 2, 2011, Pages 113-122

  Abu El Asrar, Ahmed M ^a   Al Mezaine, Hani S ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Diabetic retinopathy; Review; Treatment

Indexed keywords

BEVACIZUMAB; FENOFIBRATE; OCRIPLASMIN; PEGAPTANIB; PLACEBO; RANIBIZUMAB; RUBOXISTAURIN; TRIAMCINOLONE ACETONIDE;

CATARACT; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFICACY; GLYCEMIC CONTROL; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY DETACHMENT;

EID: 79954908975     PISSN: 13194534     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sjopt.2011.01.005     Document Type: Review

References (87)

1. Chew E.Y., Ambrosius W.T., Davis M.D., Danis R.P., Gangaputra S., Greven C.M., Hubbard L., Esser B.A., Lovato J.F., Perdue L.H., Goff D.C., Cushman W.C., Ginsberg H.N., Elam M.B., Genuth S., Gerstein H.C., Schubart U., Fine L.J. Effects of medical therapies on retinopathy progression in type 2 diabetes. N. Engl. J. Med. 2010, 363(3):233-244. Accord Study Group; Accord Eye Study Group.
2. Adamis A.P., Altaweel M., Bressler N.M., Cunningham E.T., Davis M.D., Goldbaum M., Gonzales C., Guyer D.R., Barrett K., Patel M. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006, 113(1):23-28. Macugen Diabetic Retinopathy Study Group.
3. Ahmadieh H., Shoeibi N., Entezari M., Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology 2009, 116(10):1943-1948.
4. Aiello L.P., Edwards A.R., Beck R.W., Bressler N.M., Davis M.D., Ferris F., Glassman A.R., Ip M.S., Miller K.M. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2010, 117(5):946-953. Diabetic Retinopathy Clinical Research Network.
5. Anonymous Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 1978, 85(1):82-106.
6. Arevalo J.F., Maia M., Flynn H.W., Saravia M., Avery R.L., Wu L., Eid Farah M., Pieramici D.J., Berrocal M.H., Sanchez J.G. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br. J. Ophthalmol. 2008, 92(2):213-216.
7. Arevalo J.F., Sanchez J.G., Fromow-Guerra J., Wu L., Berrocal M.H., Farah M.E., Cardillo J., Rodriguez F.J. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefes Arch. Clin. Exp. Ophthalmol. 2009, 247(6):735-743. Pan-American Collaborative Retina Study Group (PACORES).
8. Arevalo J.F., Wu L., Sanchez J.G., Maia M., Saravia M.J., Fernandez C.F., Evans T. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye 2009, 23(1):117-123.
9. Asami T., Terasaki H., Kachi S., Nakamura M., Yamamura K., Nabeshima T., Miyake Y. Ultrastructure of internal limiting membrane removed during plasmin-assisted vitrectomy from eyes with diabetic macular edema. Ophthalmology 2004, 111(2):231-237.
10. Azzolini C., D'Angelo A., Maestranzi G., Codenotti M., Della Valle P., Prati M., Brancato R. Intrasurgical plasmin enzyme in diabetic macular edema. Am. J. Ophthalmol. 2004, 138(4):560-566.
11. Beer P.M., Bakri S.J., Singh R.J., Liu W., Peters G.B., Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003, 110(4):681-686.
12. Bonini-Filho M., Costa R.A., Calucci D., Jorge R., Melo L.A., Scott I.U. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study. Am. J. Ophthalmol. 2009, 147(6):1022-1030.
13. Bressler N.M., Edwards A.R., Beck R.W., Flaxel C.J., Glassman A.R., Ip M.S., Kollman C., Kuppermann B.D., Stone T.W. Exploratory analysis or diabetic retinopathy progression through 3 years in randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch. Ophthalmol. 2009, 127(12):1566-1571. Diabetic Retinopathy Clinical Research Network.
14. Chaturvedi N., Sjølie A.K., Stephenson J.M., Abrahamian H., Keipes M., Castellarin A., Rogulja-Pepeonik Z., Fuller J.H. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998, 351(9095):28-31. The EUCLID Study Group, EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus.
15. Chaturvedi N., Porta M., Klein R., Orchard T., Fuller J., Parving H.H., Bilous R., Sjølie A.K. Effect of Candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008, 372(9647):1394-1402. DIRECT Programme Study Group.
16. Cho W.B., Oh S.B., Moon J.W., Kim H.C. Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina 2009, 29(4):516-522.
17. Chun D.W., Heier J.S., Topping T.M., Duker J.S., Bankert J.M. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006, 113(10):1706-1712.
18. Cunningham E.T., Adamis A.P., Altaweel M., Aiello L.P., Bressler N.M., D'Amico D.J., Goldbaum M., Guyer D.R., Katz B., Patel M., Schwartz S.D. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005, 112(10):1747-1757. Macugen Diabetic Retinopathy Study Group.
19. Davis M.D., Sheetz M.J., Aiello L.P., Milton R.C., Danis R.P., Zhi X., Girach A., Jimenez M.C., Vignati L. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2009, 50(1):1-4. PKC-DRS2 Study Group.
20. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993, 329(14):977-986. Diabetes Control and Complications Trial Research Group.
21. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch. Ophthalmol. 1998, 116(7):874-886. Diabetes Control and Complications Trial Research Group.
22. di Lauro R., De Ruggiero P., di Lauro R., di Lauro M.T., Romano M.R. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2010, 248(6):785-791.
23. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008, 115(9):1447-1449. Diabetic Retinopathy Clinical Research Network.
24. Beck R.W., Edwards A.R., Aiello L.P., Bressler N.M., Ferris F., Glassman A.R., Hartnett E., Ip M.S., Kim J.E., Kollman C. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch. Ophthalmol. 2009, 127(3):245-251. Diabetic Retinopathy Clinical Research Network (DRCR.net).
25. Brucker A.J., Qin H., Antoszyk A.N., Beck R.W., Brassler N.M., Browning D.J., Elman M.J., Glassman A.R., Gross J.G., Kollman C., Wells J.A. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch. Ophthalmol. 2009, 127(2):132-140. Diabetic Retinopathy Clinical Research Network.
26. Elman M.J., Beck R.W., Bressler N.M., Bressler S.B., Edwards A.R., Ferries F.L., Friedman S.M., Glassman A.R., Miller K.M., Scott I.U., Stockdale C.R., Sun J.K. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010, 117(6):1064-1077. Diabetic Retinopathy Clinical Research Network.
27. Haller J.A., Qin H., Apte R.S., Beck R.R., Bressler N.M., Browning D.J., Danis R.P., Glassman A.R., Googe J.M., Kollman C., Lauer A.K., Peters M.A., Stockman M.E. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 2010, 117(6):1087-1093. Diabetic Retinopathy Clinical Research Network Writing Committee.
28. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. Arch. Ophthalmol. 1985, 103(11):1644-1652. Diabetic Retinopathy Vitrectomy Study Research Group.
29. Diaz-Llopis M., Udaondo P., Arevalo F., Salom D., Garcia-Delpech S., Quijada A., Romero F.J. Intravitreal plasmin without associated vitrectomy as a treatment of refractory diabetic macular edema. J. Ocul. Pharmacol. Ther. 2009, 25(4):379-384.
30. Do D.V., Nguyen Q.D., Shah S.M., Browning D.J., Haller J.A., Chu K., Yang K., Cedarbaum J.M., Vitti R.L., Ingerman A., Campochiaro P.A. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br. J. Ophthalmol. 2009, 93(2):144-149.
31. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch. Ophthalmol. 1985, 103(12):1796-1806. Early Treatment Diabetic Retinopathy Study Research Group.
32. Fang X., Sakaguchi H., Gomi F., Oshima Y., Sawa M., Tsujikawa M., Ikuno Y., Kamei M., Kusaka S., Tano Y. Efficacy and safety of one intravitreal injection of bavacizumab in diabetic macular oedema. Acta Ophthalmol. 2008, 86(7):800-805.
33. Ferris F. Early photocoagulation in patients with either type I or type II diabetes. Trans. Am. Ophthalmol. Soc. 1996, 94:503-537.
34. Figueroa M.S., Contreras I., Noval S. Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema. Retina 2008, 28(3):420-426.
35. Flaxel C.J., Edwards A.R., Aiello L.P., Arrigg P.G., Beck R.W., Bressler N.M., Bressler S.B., Ferris F.L., Gupta S.K., Haller J.A., Lazarus H.S., Qin H. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: diabetic retinopathy clinical research network. Retina 2010, 30(9):1488-1495.
36. Fong D.S., Contreras R. Glitazone use associated with diabetic macular edema. Am. J. Ophthalmol. 2009, 147(4):583-586.
37. Fong D.S., Aiello L., Gardner T.W., King G.L., Blankenship G., Cavallerano J.D., Ferris FL., Klein R. American Diabetes Association, Diabetic retinopathy. Diabetes Care 2003, 26(Suppl. 1):S99-S102.
38. Gillies M.C., Sutter F.K., Simpson J.M., Larsson J., Ali H., Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006, 113(9):1533-1538.
39. González V.H., Giuliari G.P., Banda R.M., Guel D.A. Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy. Br. J. Ophthalmol. 2009, 93(11):1474-1478.
40. Hirata A., Takano A., Inomata Y., Yonemura N., Sagara N., Tanihara H. Plasmin-assisted vitrectomy for management of proliferative membrane in proliferative diabetic retinopathy: a pilot study. Retina 2007, 27(8):1074-1078.
41. Huang Y.H., Yeh P.T., Chen M.S., Yang C.H., Yang C.M. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage. Retina 2009, 29(8):1134-1140.
42. Jiang Y., Liang X., Li X., Tao Y., Wang K. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy. Acta Ophthalmol. 2009, 87(7):736-740.
43. Kang S.W., Sa H.S., Cho H.Y., Kim J.I. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch. Ophthalmol. 2006, 124:653-658.
44. Keech A.C., Mitchell P., Summanen P.A., O'Day J., Davis T.M., Moffitt M.S., Taskinen M.R., Simes R.J., Tse D., Williamson E., Merrifield A., Laatikainen L.T., d'Emden M.C., Crimet D.C., O'Connell R.L., Colman P.G. FIELD study investigators, effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007, 370(9600):1687-1697.
45. Kumagai K., Furukawa M., Ogino N., Larson E., Iwaki M., Tachi N. Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema. Retina 2009, 29(4):464-472.
46. Kuppermann B.D., Thomas E.L., de Smet M.D., Grillone L.R. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am. J. Ophthalmol. 2005, 140(4):573-584.
47. Kuppermann B.D., Thomas E.L., de Smet M.D., Grillone L.R. Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am. J. Ophthalmol. 2005, 140(4):585-597.
48. Lam D.S., Chan C.K., Mohamed S., Lai T.Y., Lee V.Y., Liu D.T., Li K.K., Li P.S., Shanmugam M.P. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes. Ophthalmology 2007, 114(12):2162-2167.
49. Lam D.S., Lai T.Y., Lee V.Y., Chan C.K., Liu D.T., Mohamed S., Li C.L. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. Retina 2009, 29(3):292-299.
50. Lanzagorta-Aresti A., Palacios-Pozo E., Menezo Rozalen J.L., Navea-Tejerina A. Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: a pilot study. Retina 2009, 29(4):530-535.
51. Lo W.R., Kim S.J., Aaberg T.M., Bergstrom C., Srivastava S.K., Yan J., Martin D.F., Hubbard G.B. Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bavacizumab (avastin). Retina 2009, 29(7):926-931.
52. Maia O.O., Takahashi B.S., Costa R.A., Scott I.U., Takahashi W.Y. Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: one-year results of a randomized clinical trial. Am. J. Ophthalmol. 2009, 147(2):291-297.
53. Mirshahi A., Shenazandi H., Lashay A., Faghihi H., Alimahmoudi A., Dianat S. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema. Retina 2010, 30(2):254-259.
54. Muranaka K., Yanagi Y., Tamaki Y., Usui T., Kubota N., Iriyama A., Terauchi Y., Kadowaki T., Araie M. Effects of peroxisome proliferator-activated receptor gamma and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model. Invest. Ophthalmol. Vis. Sci. 2006, 47(10):4547-4552.
55. Nguyen Q.D., Shah S.M., Heier J.S., Do D.V., Lim J., Boyer D., Abraham P., Campochiaro P.A. Primary end point (Six Months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology 2009, 116(11):2175-2181. READ-2 Study Group.
56. Nguyen Q.D., Shah S.M., Khwaja A.A., Channa R., Hatef E., Do D.V., Boyer D., Heier J.S., Abraham P., Thach A.B., Lit E.S., Foster B.S., Kruger E., Dugel P., Chang T., Das A., Ciulla T.A., Pollack J.S., Lim J.I., Eliot D., Campochiaro P.A. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010, 117(11):2146-2151. READ-2 Study Group.
57. Paccola L., Costa R.A., Folgosa M.S., Barbosa J.C., Scott I.U., Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br. J. Ophthalmol. 2008, 92(1):76-80.
58. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch. Ophthalmol. 2007, 125(3):318-324. PKC-DMES Study Group.
59. Aiello L.P., Davis M.D., Girach A., Kles K.A., Milton R.C., Sheetz M.J., Vignati L., Zhi X.E. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006, 113(12):2221-2230. PKC-DRS2 Group.
60. Querques G., Bux A.V., Martinelli D., Iaculli C., Noci N.D. Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema. Acta Ophthalmol 2009, 87(6):623-630.
61. Quiram P.A., Leverenz V.R., Baker R.M., Dang L., Giblin F.J., Trese M.T. Microplasmin-induced posterior vitreous detachment affects vitreous oxygen levels. Retina 2007, 27(8):1090-1096.
62. Roh M.I., Byeon S.H., Kwon W.O. Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema. Retina 2008, 28(9):1314-1318.
63. Romano M.R., Gibran S.K., Marticorena J., Wong D., Heimann H. Can an intraoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous hemorrhage?. Eur. J. Ophthalmol. 2009, 19(4):618-621.
64. Rudnisky C.J., Lavergne V., Katz D. Visual acuity after intravitreal triamcinolone for diabetic macular edema refractory to laser treatment: a meta-analysis. Can. J. Ophthalmol. 2009, 44(5):587-593.
65. Sakuma T., Tanaka M., Inoue J., Mizota A., Souri M., Ichinose A. Use of autologous plasmin during vitrectomy for diabetic maculopathy. Eur. J. Ophthalmol. 2006, 16:138-140.
66. Shah S.P., Patel M., Thomas D., Aldington S., Laidlaw D.A. Factors predicting outcome of vitrectomy for diabetic macular oedema: results of a prospective study. Br. J. Ophthalmol. 2006, 90(1):33-36.
67. Shen L.Q., Child A., Weber G.M., Folkman J., Aiello L.P. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch. Ophthalmol. 2008, 126(6):793-799.
68. Shiba T., Kamura Y., Yagi F., Sato Y. Comparison of surgical procedures for vitreous surgery in diabetic macular edema. Jpn. J. Ophthalmol. 2009, 53(2):120-124.
69. Shimura M., Nakazawa T., Yasuda K., Shiono T., Iida T., Sakamoto T., Nishida K. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am. J. Ophthalmol. 2008, 145(5):854-861.
70. Sjølie A.K., Klein R., Porta M., Orchard T., Fuller J., Parving H.H., Bilous R., Chaturvedi N. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008, 372(9647):1385-1393. DIRECT Programme Study Group.
71. Soheilian M., Ramezani A., Obudi A., Bijanzadeh B., Salehipour M., Yaseri M., Ahmadieh H., Dehghan M.H., Azarmina M., Moradian S., Peyman G.A. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009, 116(6):1142-1150.
72. Stefánsson E. Physiology of vitreous surgery. Graefes Arch. Clin. Exp. Ophthalmol. 2009, 247(2):147-163.
73. Stolba U., Binder S., Gruber D., Krebs I., Aggermann T., Neumaier B. Vitrectomy for persistent diffuse diabetic macular edema. Am. J. Ophthalmol. 2005, 140(2):295-301.
74. Takamura Y., Kubo E., Akagi Y. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery. Ophthalmology 2009, 116(6):1151-1157.
75. Tatti P., Arrigoni F., Longobardi A., Costanza F., Di Blasi P., Merante D. Retrospective analysis of rosiglitazone and macular oedema in patients with type 2 diabetes mellitus. Clin. Drug Investig. 2008, 28(5):327-332.
76. Thompson D.M., Begg I.S., Harris C., Ao Z., Fung M.A., Meloche R.M., Keown P., Meneilly G.S., Shapiro R.J., Ho S., Dawson K.G., Al Ghofaili K., Al Riyami L., Al Mehthel M., Kozak S.E., Tong S.O., Warnock G.L. Reduced progression of diabetic retinopathy after islet cell transplantation compared with intensive medical therapy. Transplantation 2008, 85(10):1400-1405.
77. Tonello M., Costa R.A., Almeida F.P., Barbosa J.C., Scott I.U., Jorge R. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol. 2008, 86(4):385-389.
78. Intensive blood-glucose control with sul phonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352(9131):837-853. UK Prospective Diabetes Study (UKPDS) Group.
79. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317(7160):703-713. UK Prospective Diabetes Study Group.
80. Wakabayashi T., Oshima Y., Sakaguchi H., Ikuno Y., Miki A., Gomi F., Otori Y., Kamei M., Kusaka S., Tano Y. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008, 115(9):1571-1580.
81. Warnock G.L., Thompson D.M., Meloche R.M., Shapiro R.J., Ao Z., Keown P., Johnson J.D., Verchere C.B., Partovi N., Begg I.S., Fung M., Kozak S.E., Tong S.O., Alghofaili K.M., Harris C. A multi-year analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes. Transplantation 2008, 86(12):1762-1766.
82. White N.H., Sun W., Cleary P.A., Danis R.P., Davis M.D., Hainsworth D.P., Hubbard L.D., Lachin J.M., Nathan D.M. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch. Ophthalmol. 2008, 126(12):1707-1715.
83. Fong D.S., Strauber S.F., Aiello L.P., Beck R.W., Callanan D.G., Danis R.P., Davis M.D., Feman S.S., Ferris F., Friedman S.M., Garcia C.A., Glassman A.R., Han D.P., Le D., Kollman C., Lauer A.K., Recchia F.M., Solomon S.D. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch. Ophthalmol. 2007, 125(4):469-480. Writing Committee for the Diabetic Retinopathy Clinical Research Network.
84. Yamamoto T., Takeuchi S., Sato Y., Yamashita H. Long-term follow-up results of pars plana vitrectomy for diabetic macular edema. Jpn. J. Ophthalmol. 2007, 51(4):285-291.
85. Yanyali A., Aytug B., Horozoglu F., Nohutcu A.F. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am. J. Ophthalmol. 2007, 144(1):124-126.
86. Yilmaz T., Weaver C.D., Gallagher M.J., Cordero-Coma M., Cervantes-Castaneda R.A., Klisovic D., Lavaque A.J., Larson R.J. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology 2009, 116(5):902-911.
87. Zhi-Liang W., Wo-Dong S., Min L., Xiao-Ping B., Jin J. Pharmacologic vitreolysis with plasmin and hyaluronidase in diabetic rats. Retina 2009, 29(2):269-274.